Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.
LivaNova PLC (NASDAQ:LIVN) announced the randomization of the 300th patient in its ANTHEM-HFrEF Pivotal Study, aiming to evaluate Autonomic Regulation Therapy (ART) for heart failure treatment. This FDA-approved study will analyze the effectiveness of Vagus Nerve Stimulation (VNS) on symptoms and clinical outcomes in heart failure patients with reduced ejection fraction. The VITARIA System, designed for ART delivery, may become a first-in-class device if approved. Notable clinical outcomes include symptom relief and reduced hospitalizations.
LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will host a conference call on April 28, 2021, at 12 p.m. London time (7 a.m. EDT) to discuss its Q1 2021 results. The results will be released prior to the call. Interested listeners can access a live audiocast via the Investors section of LivaNova's website. The dial-in numbers include 844-558-0159 for U.S. and Canada and 236-714-3182 for other regions, with a conference ID of 6493742. A replay will be available for 90 days following the call.
LivaNova PLC (NASDAQ: LIVN) reported a Q4 2020 revenue of $269.6 million, a 6.3% decline compared to Q4 2019, impacted by COVID-19. The diluted loss per share was $5.74, while adjusted EPS was $0.71. Cardiovascular sales fell by 10.1%, with Heart Valves down 27.2%, but Advanced Circulatory Support saw a 50.3% increase. For FY 2020, total sales decreased by 13.8% to $934.2 million. Looking ahead, LivaNova forecasts 2021 sales growth of 8-13% and adjusted EPS between $1.40 and $1.90, despite ongoing COVID-related uncertainties.
LivaNova PLC (NASDAQ:LIVN) will hold a conference call on February 24, 2021, at 1 p.m. London time (8 a.m. EST) to discuss its fourth quarter and full-year 2020 results, which will be released prior to the call. Interested parties can access a live audiocast on LivaNova's Investor Relations website. For phone access, dial 844-239-5285 or 512-961-6524, using conference ID 1290829. A replay will be available for 90 days post-call. LivaNova is a global medical technology company dedicated to innovative healthcare solutions, serving over 100 countries.
LivaNova PLC (NASDAQ:LIVN) will host a virtual symposium titled "Updates and Advances in Neuromodulation" at AES2020 on December 6, 2020, from 6 to 8:30 p.m. ET. The event will feature leading clinicians discussing the role of VNS Therapy in treating drug-resistant epilepsy (DRE) and other disorders. Attendees will explore the economic and healthcare burdens of DRE and learn how VNS Therapy can alleviate these challenges. The symposium is free for AES2020 registrants, and a recording will be available afterward.
LivaNova PLC (NASDAQ:LIVN) has announced a strategic divestiture of its heart valve (HV) business to Gyrus Capital for an enterprise value of €60 million (US$73 million). The deal, unanimously approved by LivaNova's Board of Directors, aims to enhance focus on neuromodulation and cardiovascular platforms. The transaction is expected to be dilutive to earnings per share by approximately 10-15 cents in 2021 and may trigger a non-cash impairment charge of US$200 million to US$225 million. Completion is targeted for the first half of 2021, pending regulatory approvals.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will speak at the Berenberg European Conference 2020 on December 2 at 4 p.m. GMT. Attendees should log in 10 minutes early to prepare for the audiocast. A replay will be available on LivaNova's website within 24 hours for 90 days. Established nearly 50 years ago, LivaNova is a leading global medical technology company focused on innovative solutions for patients’ heart and brain health, employing around 4,000 people across more than 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will engage in discussions at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3. A pre-recorded discussion will be available on November 23 at 10 a.m. Eastern via LivaNova's Investor Relations webpage. The recording will remain accessible for 90 days, and conference meetings by invitation will occur on December 3. LivaNova, a leading medical technology company headquartered in London, has over 4,000 employees and serves more than 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the Stifel 2020 Virtual Healthcare Conference on November 17 at 10:40 a.m. ET. The live discussion will be accessible via a webcast on the company's Investors section of their website. A replay will be available for 90 days following the event. LivaNova, headquartered in London, focuses on innovative medical technologies across two business sectors: Cardiovascular and Neuromodulation, serving over 100 countries worldwide.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
